Bladder Cancer Highlights from SIU 2017 - Thomas Keane

Dr. Thomas Keane reviews recent data presented at the SIU 2017 conference focusing on urothelial carcinoma. Highlighting a number of presentations, he focuses on Translational Observations from Mutation Profiling of Muscle Invasive Bladder Cancer a presentation by Seth Lerner  and details his summary slide with 5 subtypes and proposed paradigm for management.  He also discusses another presentation by Seth Lerner on Comprehensive Molecular Characterization and Analysis of Muscle-invasive Urothelial Carcinomas.  He overviews Badrinath Konety's presentation Neoadjuvant Chemo - When, What and Why? and concludes with Can Genetic Analysis in Bladder Cancer Enhance Decision Making by Peter Black.  He reflects on the recent accomplishments in bladder cancer and the work that has strengthened the risk stratification of patients prior to neoadjutvant chemotherapy. 

Read the Conference Commentaries Discussed by Dr. Keane

Translational Observations from Mutation Profiling of Muscle Invasive Bladder Cancer

Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas.

Neoadjuvant Chemo - When, What and Why?

Can Genetic Analysis in Bladder Cancer Enhance Decision Making

SIU-ICUD Joint Consultation on Bladder Cancer - Urinary Diversion

A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS